<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Evaluation of the incidental kidney lesion</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Evaluation of the incidental kidney lesion</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Evaluation of the incidental kidney lesion</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Shauna Duigenan, MD, FRCPC</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert G Uzzo, MD, MBA, FACS</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Herbert Y Kressel, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Deborah A Baumgarten, MD, MPH</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Eric N Taylor, MD, MSc, FASN</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 06, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1442109015"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>With increasing utilization of cross-sectional imaging such as ultrasound (US), computed tomography (CT), and magnetic resonance imaging (MRI), the detection rates of an incidental kidney lesion have increased over time [<a href="#rid1">1,2</a>]. While many incidental kidney lesions can be left alone as they will have no clinical consequences, some are pathologies (eg, renal cell carcinoma, renal pseudoaneurysm) that could have an impact on patient outcomes.</p><p>Here we describe an approach for evaluating an incidental kidney lesion. The goal of the evaluation is to select those that require further management from those that can be left alone because they are of no clinical significance. The management of kidney lesions once they have been labeled with a suspected diagnosis is described in:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1681.html" rel="external">"Simple and complex kidney cysts in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/90017.html" rel="external">"Renal angiomyolipomas (AMLs): Management"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/2970.html" rel="external">"Diagnostic approach, differential diagnosis, and management of a small renal mass"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/2983.html" rel="external">"Clinical manifestations, evaluation, and staging of renal cell carcinoma"</a>.)</p><p></p><p>The diagnostic approach to a kidney lesion found during evaluation for urinary-related symptoms would be different than the approach described here. The management of such kidney lesions are described in UpToDate according to their clinical presentation.</p><p class="headingAnchor" id="H913895925"><span class="h1">APPROACH TO THE DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>An incidental kidney lesion is one detected on imaging performed for reasons other than for evaluation of urinary signs or symptoms [<a href="#rid3">3</a>].</p><p>The diagnostic approach to the incidental kidney lesion is to differentiate the vast majority of those that require no further evaluation from those that require referral for management. If the lesion does not demonstrate features characteristic of a specific diagnosis at detection, dedicated kidney imaging is performed. Based on the imaging features, the lesion is left alone as having no clinical consequences or triaged for further management that includes surveillance imaging, biopsy, or treatment targeted toward the suspected diagnosis.</p><p>Most incidental kidney lesions are cysts, which are seen in up to 40 percent of adults who undergo abdominal computed tomography (CT) [<a href="#rid2">2</a>]. Simple cysts represent the most commonly detected incidental kidney lesion. They are benign, asymptomatic lesions that rarely require treatment [<a href="#rid4">4,5</a>]. However, among other incidental kidney lesions are benign tumors (eg, angiomyolipoma, oncocytoma), malignant tumors (eg, renal cell carcinoma), and vascular lesions (eg, arteriovenous fistula, renal artery aneurysm, or pseudoaneurysm) [<a href="#rid6">6-10</a>]. These also typically present as incidental kidney lesions but do require further patient evaluation and treatment.</p><p class="headingAnchor" id="H2879349429"><span class="h1">LESIONS SOMETIMES DIAGNOSED AT PRESENTATION</span><span class="headingEndMark"> — </span>Some incidental lesions can be diagnosed based on imaging features at detection  (<a class="graphic graphic_table graphicRef131673" href="/d/graphic/131673.html" rel="external">table 1</a>). </p><p class="headingAnchor" id="H575169875"><span class="h2">Simple cyst</span><span class="headingEndMark"> — </span>Simple cysts are the most commonly encountered incidental kidney lesions. In the Bosniak system for classifying kidney cysts, they belong in category I  (<a class="graphic graphic_table graphicRef67087" href="/d/graphic/67087.html" rel="external">table 2</a>) [<a href="#rid11">11</a>]. If an incidental kidney lesion demonstrates imaging features of a simple cyst at presentation, no further evaluation is warranted. (See  <a class="medical medical_review" href="/d/html/1681.html" rel="external">"Simple and complex kidney cysts in adults", section on 'Diagnosis of simple cysts'</a>.)</p><p class="headingAnchor" id="H1681620658"><span class="h2">Hemorrhagic or proteinaceous cyst</span><span class="headingEndMark"> — </span>A benign hemorrhagic or proteinaceous cyst may be diagnosed with noncontrast CT if all the following criteria are met [<a href="#rid3">3,12</a>]: </p><p class="bulletIndent1"><span class="glyph">●</span>Does not contain fat (ie, no fat attenuation)</p><p class="bulletIndent1"><span class="glyph">●</span>Homogenous internal fluid of ≥70 Hounsfield units (HU) </p><p class="bulletIndent1"><span class="glyph">●</span>A thin wall without mural nodules</p><p class="bulletIndent1"><span class="glyph">●</span>No septa or calcifications</p><p></p><p>Cysts with these characteristics on noncontrast CT do not require further evaluation.</p><p class="headingAnchor" id="H3624244779"><span class="h2">Angiomyolipoma</span><span class="headingEndMark"> — </span>Angiomyolipomas are benign neoplasms comprised of smooth muscle, adipose, and epithelioid cells. They can be diagnosed on CT or MRI if they demonstrate macroscopic fat. However, up to 5 percent of angiomyolipomas have no visible fat. (See  <a class="medical medical_review" href="/d/html/131412.html" rel="external">"Renal angiomyolipomas (AMLs): Epidemiology, pathogenesis, clinical manifestations, and diagnosis", section on 'Clinical manifestations'</a>.)</p><p>By US, angiomyolipomas are hyperechoic, although US cannot reliably distinguish them from other hyperechoic lesions. By CT, angiomyolipomas are hypoattenuating (&lt;-10 HU) with variable contrast enhancement  (<a class="graphic graphic_diagnosticimage graphicRef142870" href="/d/graphic/142870.html" rel="external">image 1</a>). By MRI, angiomyolipomas are T1-hyperintense with variable contrast enhancement and lose signal on fat suppression sequences  (<a class="graphic graphic_diagnosticimage graphicRef142874" href="/d/graphic/142874.html" rel="external">image 2</a>) [<a href="#rid13">13,14</a>]. (See  <a class="medical medical_review" href="/d/html/131412.html" rel="external">"Renal angiomyolipomas (AMLs): Epidemiology, pathogenesis, clinical manifestations, and diagnosis", section on 'How to establish a diagnosis'</a>.)</p><p class="headingAnchor" id="H3859062970"><span class="h2">Vascular abnormalities</span><span class="headingEndMark"> — </span>Vascular abnormalities include aneurysms, pseudoaneurysms, arteriovenous fistulas, and arteriovenous malformations. They may be congenital or sequela of trauma, inflammation, or interventions such as biopsy, percutaneous nephrostomy, or partial nephrectomy. By Doppler US, these lesions generally have high velocity turbulent blood flow  (<a class="graphic graphic_diagnosticimage graphicRef142875" href="/d/graphic/142875.html" rel="external">image 3</a>) [<a href="#rid9">9,10</a>]. On CT or MRI with contrast administration, these lesions have a characteristic tubular or saccular form that follows the enhancement pattern of blood vessels  (<a class="graphic graphic_diagnosticimage graphicRef142875" href="/d/graphic/142875.html" rel="external">image 3</a> and <a class="graphic graphic_diagnosticimage graphicRef142877" href="/d/graphic/142877.html" rel="external">image 4</a>). Such lesions may require intervention to reduce the risk of hemorrhage. (See <a class="local">'Vascular abnormalities'</a> below.) </p><p class="headingAnchor" id="H2244757086"><span class="h2">Malignancy</span><span class="headingEndMark"> — </span>Solid contrast-enhancing lesions measuring &gt;4 cm in diameter and containing no fat on CT or MRI have a greater than 90 percent likelihood of being malignant [<a href="#rid6">6,15</a>]. By US, such lesions will have variable echogenicity, smooth or irregular margins, and may have areas of vascularity visible by Doppler. However, these lesions cannot be reliably diagnosed by US and usually require tissue diagnosis and/or additional cross-sectional imaging for staging and treatment planning. (See  <a class="medical medical_review" href="/d/html/2983.html" rel="external">"Clinical manifestations, evaluation, and staging of renal cell carcinoma"</a>.)</p><p>While smaller, solid enhancing lesions are more likely to be benign than their larger counterparts, over 80 percent of solid enhancing lesions measuring 1 to 4 cm are malignant [<a href="#rid6">6,15</a>]. Most are renal cell carcinomas, and some are high grade or advanced stage. Among patients with a known nonrenal primary malignancy, they can also represent metastases [<a href="#rid16">16</a>]. (See <a class="local">'&lt;1 cm solid enhancing mass'</a> below and <a class="local">'1 to 4 cm solid enhancing mass'</a> below and  <a class="medical medical_review" href="/d/html/2970.html" rel="external">"Diagnostic approach, differential diagnosis, and management of a small renal mass"</a>.)</p><p class="headingAnchor" id="H2377805656"><span class="h2">Lesion measuring &lt;3 cm stable for over five years</span><span class="headingEndMark"> — </span>With incidental kidney lesions measuring &lt;3 cm lacking specific radiographically concerning features of malignancy (eg, growth into adjacent vessels or collecting system, lymphadenopathy), the patient's medical record should be searched for prior imaging examinations to assess for stability. </p><p>No change in appearance (eg, contour, number of septa, internal heterogeneity, attenuation, signal, or echotexture) or change in size indicates a stable lesion [<a href="#rid3">3,17,18</a>]. Longitudinal surveillance series indicate that such lesions rarely metastasize and are probably either benign or indolent renal cell carcinoma [<a href="#rid19">19,20</a>]. Hence, lesions demonstrating long-term (ie, &gt;5 years) stability are thought unlikely to impact patient outcome over the ensuing decade [<a href="#rid21">21,22</a>].</p><p class="headingAnchor" id="H3740039934"><span class="h1">DEDICATED KIDNEY IMAGING</span><span class="headingEndMark"> — </span>While some incidental kidney lesions can be diagnosed at detection, many require dedicated kidney imaging before a management decision can be made. </p><p class="headingAnchor" id="H2966525156"><span class="h2">Choice of imaging modality</span><span class="headingEndMark"> — </span>With the exception of simple and some hemorrhagic or proteinaceous cysts (see <a class="local">'Hemorrhagic or proteinaceous cyst'</a> above), abdominal computed tomography (CT) or magnetic resonance imaging (MRI) without and with contrast tailored for kidney lesion characterization is usually required to manage incidental kidney lesions [<a href="#rid23">23</a>]. The image acquisition protocols for kidney lesion characterization are more stringent than those for routine abdominal imaging and, therefore, most patients require another dedicated CT or MRI examination (with kidney mass protocol) following the one on which the lesion was incidentally detected.</p><p>In patients with severe kidney function impairment (ie, estimated glomerular filtration rate [eGFR] &lt;30 mL/min/1.73 m<sup>2</sup>), iodinated contrast agents may be contraindicated. Instead, MRI without and with gadolinium or ultrasound without and with contrast should be performed. However, the use of group I gadolinium-based contrast agents should be avoided in such patients. (See  <a class="medical medical_review" href="/d/html/113083.html" rel="external">"Patient evaluation prior to oral or iodinated intravenous contrast for computed tomography", section on 'Patients with eGFR &lt;30'</a> and  <a class="medical medical_review" href="/d/html/113082.html" rel="external">"Patient evaluation before gadolinium contrast administration for magnetic resonance imaging", section on 'Patients with eGFR &lt;30 mL/min/1.73 m2 or with acute kidney injury'</a>.)</p><p>In most practice settings where contrast-enhanced US is not available, MRI without contrast is performed as the second-line option. MRI without contrast is preferred over CT without contrast because the former yields more tissue-specific information. In this setting, addition of diffusion weighted sequences and analysis of apparent diffusion coefficient maps may improve diagnostic accuracy [<a href="#rid24">24,25</a>]. </p><p>Availability of imaging technology and expertise at the site usually drives the choice between CT versus MRI for kidney lesion characterization. However, MRI is generally preferred for small lesions (eg, &lt;1.5 cm) [<a href="#rid3">3</a>]. As intravenous contrast is routinely given for this indication, a history of an acute adverse reaction to iodinated contrast for CT or to gadolinium-based contrast for MRI may determine the choice. Other patient-related factors include indwelling electrical or metallic implants or severe claustrophobia, both of which are relative contraindications to MRI. (See  <a class="medical medical_review" href="/d/html/113083.html" rel="external">"Patient evaluation prior to oral or iodinated intravenous contrast for computed tomography", section on 'Patients with past reactions to contrast'</a> and  <a class="medical medical_review" href="/d/html/113082.html" rel="external">"Patient evaluation before gadolinium contrast administration for magnetic resonance imaging", section on 'Patient with history of reaction to gadolinium contrast'</a> and  <a class="medical medical_review" href="/d/html/113084.html" rel="external">"Patient evaluation for metallic or electrical implants, devices, or foreign bodies before magnetic resonance imaging"</a>.)</p><p class="headingAnchor" id="H3611300850"><span class="h2">CT and MRI imaging</span><span class="headingEndMark"> — </span>Visual and, in some cases, quantitative assessment for solid tissue that enhances with intravenous contrast are the most important aspects of the dedicated kidney imaging examination. The protocol is also directed at detecting fluid, fat, or calcification within the lesion. Abdominal CT or MRI that include kidneys within the field of view but obtained for other indications (eg, MRI of the lumbar spine, CT of the abdomen for pain, etc) will usually not be sufficient to fully characterize a kidney lesion.</p><p>Dedicated CT or MRI for kidney lesion evaluation is characterized by high resolution images through the kidneys before and after contrast administration. Typically, axial ≤5 mm-thick slices through the kidneys before and after bolus administration of intravenous contrast is performed. Postcontrast imaging is acquired in the nephrographic phase of the bolus to assess lesion enhancement. Subtraction imaging of pre- from postcontrast images are sometimes created to increase the conspicuity of enhancing tissue [<a href="#rid26">26,27</a>]. With dual energy CT, where virtual noncontrast images can be generated after iodine quantification, postcontrast images alone may be sufficient for kidney lesion characterization and affords diagnostic accuracy comparable with pre- and postcontrast imaging with conventional CT [<a href="#rid28">28,29</a>].</p><p>Additional steps in the imaging protocol vary with each practice and are intended to improve diagnostic accuracy. With CT, multiplanar reformats in the coronal and sagittal plane improve conspicuity for small enhancing kidney masses [<a href="#rid30">30,31</a>]. With MRI, T1-weighted images without and with fat saturation and T2-weighted images are obtained before intravenous contrast administration for tissue characterization (eg, fat, hemorrhage, fluid) [<a href="#rid32">32</a>]. Some practices include imaging in the arterial and/or venous phase after bolus contrast administration for vessel evaluation and/or in the excretory phase to evaluate the intrarenal collecting system for urothelial malignancies that can present as a central kidney mass. </p><p>Both CT and MRI demonstrate high sensitivities (approximately 90 percent) for detecting renal cell carcinoma [<a href="#rid33">33</a>]. MRI, with greater capability for soft tissue contrast, has a higher specificity than CT (89 versus 75 percent, respectively) and, hence, results in fewer false-positive diagnoses.</p><p>Effective radiation dose of CT for kidney lesion evaluation is approximately 5 to 10 mSv. MRI does not involve radiation exposure for the patient.</p><p class="headingAnchor" id="H1221790868"><span class="h2">Limited use of contrast-enhanced ultrasound</span><span class="headingEndMark"> — </span>US assessment enables differentiation of a cystic versus solid incidental kidney lesion. With addition of Doppler, it can often characterize high flow vascular lesions (eg, aneurysms, pseudoaneurysms, arteriovenous fistulas). Intravenous contrast is administered to assess enhancement of the solid components. US contrast agents can be given safely to patients with severe kidney function impairment in whom CT or MRI contrast agents are relatively contraindicated. However, contrast-enhanced ultrasound is not a widely available technology and the data regarding its diagnostic performance, albeit growing, remain limited [<a href="#rid34">34-37</a>].</p><p class="headingAnchor" id="H1454140095"><span class="h1">LESIONS NOT REQUIRING FURTHER MANAGEMENT AFTER KIDNEY IMAGING</span><span class="headingEndMark"> — </span>Following dedicated kidney imaging, some incidental lesions are characterized as clinically insignificant, requiring no additional management. </p><p class="headingAnchor" id="H3480396942"><span class="h2">Pseudotumor</span><span class="headingEndMark"> — </span>Renal pseudotumors are developmental variants or sequela of prior infection that mimic a renal neoplasm on ultrasound (US). These include a prominent column of Bertin  (<a class="graphic graphic_diagnosticimage graphicRef142878" href="/d/graphic/142878.html" rel="external">image 5</a> and <a class="graphic graphic_diagnosticimage graphicRef142917" href="/d/graphic/142917.html" rel="external">image 6</a>), a dromedary hump of the left kidney, a persistent fetal lobulation, and severe scarring with adjacent hypertrophy of the renal parenchyma. Clinical scenarios suggestive of a pseudotumor include a solitary kidney, which are more likely to demonstrate a hypertrophied column of Bertin or a history of vesicoureteral reflux, pyelonephritis, or treatments for nephrolithiasis, which may result in scarring. Pseudotumors can be diagnosed based on their characteristic appearance on dedicated kidney imaging with computed tomography (CT) or magnetic resonance imaging (MRI). </p><p class="headingAnchor" id="H3726003442"><span class="h2">Bosniak I or II cyst</span><span class="headingEndMark"> — </span>Incidental cystic kidney lesions are classified based on the degree of complexity (eg, solid component, calcifications) and categorized on their likelihood of underlying malignancy according to the Bosniak criteria [<a href="#rid5">5</a>]. Bosniak I (ie, simple cyst) and Bosniak II (ie, minimally complex cysts) are benign and require no further evaluation  (<a class="graphic graphic_diagnosticimage graphicRef100055" href="/d/graphic/100055.html" rel="external">image 7</a>). (See  <a class="medical medical_review" href="/d/html/1681.html" rel="external">"Simple and complex kidney cysts in adults", section on 'Management according to Bosniak category'</a>.)</p><p class="headingAnchor" id="H1728340043"><span class="h1">LESIONS REQUIRING FURTHER MANAGEMENT AFTER KIDNEY IMAGING</span><span class="headingEndMark"> — </span>Following dedicated kidney imaging, some incidental lesions require treatment or follow-up.</p><p class="headingAnchor" id="H3528432481"><span class="h2">Lesions with equivocal enhancement on CT</span><span class="headingEndMark"> — </span>A kidney lesion with an increase in attenuation between 10 and 20 Hounsfield units (HU) following intravenous contrast is defined as demonstrating equivocal enhancement [<a href="#rid3">3</a>]. These could represent a solid mass with low-grade enhancement (eg, papillary renal cell carcinoma) or a benign cyst. Usually, these are further evaluated with magnetic resonance imaging (MRI), which affords greater tissue contrast to differentiate soft tissue from fluid. However, contrast-enhanced ultrasound (US) or dual-energy computed tomography (CT) may be chosen for further evaluation in some practices, depending on the availability of necessary technology and expertise.</p><p class="headingAnchor" id="H3081699075"><span class="h2">Bosniak IIF, III, or IV cyst</span><span class="headingEndMark"> — </span>Bosniak IIF, III, and IV lesions include benign complex cysts and cystic renal cell carcinomas  (<a class="graphic graphic_diagnosticimage graphicRef87864" href="/d/graphic/87864.html" rel="external">image 8</a> and <a class="graphic graphic_diagnosticimage graphicRef142922" href="/d/graphic/142922.html" rel="external">image 9</a>). The likelihood of underlying malignancy in a cystic kidney lesion increases with its complexity and the corresponding Bosniak category. Reported rates of malignancy from observational series range between 25 to 85 percent, depending on the category [<a href="#rid38">38,39</a>]. Consequently, these lesions require additional evaluation that involves surveillance imaging, biopsy, or resection. (See  <a class="medical medical_review" href="/d/html/1681.html" rel="external">"Simple and complex kidney cysts in adults", section on 'Management according to Bosniak category'</a>.)</p><p class="headingAnchor" id="H3477241455"><span class="h2">Angiomyolipoma</span><span class="headingEndMark"> — </span>Angiomyolipomas require further management because of the risk for hemorrhage, which depends partly on their size and growth rate [<a href="#rid40">40,41</a>]. (See  <a class="medical medical_review" href="/d/html/90017.html" rel="external">"Renal angiomyolipomas (AMLs): Management"</a>.)</p><p class="headingAnchor" id="H4004450740"><span class="h2">Focal infection</span><span class="headingEndMark"> — </span>Focal pyelonephritis  (<a class="graphic graphic_diagnosticimage graphicRef142923" href="/d/graphic/142923.html" rel="external">image 10</a>), abscess, or xanthogranulomatous pyelonephritis can present as an incidental kidney lesion. The diagnosis is suspected based on appearance of inflammation or edema surrounding the lesion in patients with chronic nephrolithiasis or history of recurrent urinary tract infections, and confirmed with urinalysis and, rarely, biopsy. (See  <a class="medical medical_review" href="/d/html/8058.html" rel="external">"Xanthogranulomatous pyelonephritis"</a> and  <a class="medical medical_review" href="/d/html/8057.html" rel="external">"Renal and perinephric abscess"</a>.)</p><p class="headingAnchor" id="H1921442404"><span class="h2">Vascular abnormalities</span><span class="headingEndMark"> — </span>Aneurysms, pseudoaneurysms, and arteriovenous fistulas or malformations are associated with hematuria and a risk for hemorrhage. They are managed with surveillance or treated with endovascular embolization or resection.</p><p class="headingAnchor" id="H2980100292"><span class="h3">Aneurysms</span><span class="headingEndMark"> — </span>Surgical or endovascular repair or, if needed, nephrectomy is indicated for a renal arterial aneurysm that displays one of the following features:</p><p class="bulletIndent1"><span class="glyph">●</span>Size ≥2 cm</p><p class="bulletIndent1"><span class="glyph">●</span>Growth on serial imaging</p><p class="bulletIndent1"><span class="glyph">●</span>Dissection</p><p class="bulletIndent1"><span class="glyph">●</span>Thrombus with evidence of distal embolization</p><p class="bulletIndent1"><span class="glyph">●</span>Associated with kidney ischemia and hypertension or with local symptoms (eg, flank pain, hematuria)</p><p class="bulletIndent1"><span class="glyph">●</span>In a woman of child-bearing age who is likely to conceive</p><p></p><p>Aneurysms with none of these features are usually managed with periodic CT or MRI to ensure stability.</p><p class="headingAnchor" id="H713623894"><span class="h3">Pseudoaneurysms and arteriovenous fistulas or malformations</span><span class="headingEndMark"> — </span>Pseudoaneurysms and arteriovenous fistulas are a sequela of trauma, either spontaneous or iatrogenic (eg, biopsy, partial nephrectomy, percutaneous nephrostomy); arteriovenous malformations are congenital. These vascular abnormalities may be managed expectantly or treated with endovascular embolization depending on the clinical circumstances.</p><p>The majority of fistulas occurring after needle biopsy are diagnosed because of symptoms, most commonly pain or hematuria. Postbiopsy fistulas are likely underdiagnosed and most resolve spontaneously [<a href="#rid42">42</a>]. Fistulas diagnosed immediately after kidney trauma have also been noted to resolve spontaneously. </p><p>Treatment with endovascular embolization is indicated for pseudoaneurysms and arteriovenous fistulas or malformations that demonstrate:</p><p class="bulletIndent1"><span class="glyph">●</span>Associated symptoms (eg, hypertension, heart failure, severe hematuria, worsening kidney function)</p><p class="bulletIndent1"><span class="glyph">●</span>Growth on serial imaging</p><p class="bulletIndent1"><span class="glyph">●</span>Rupture on imaging</p><p class="bulletIndent1"><span class="glyph">●</span>Lack of spontaneous resolution after 18 months</p><p></p><p class="headingAnchor" id="H2747678911"><span class="h2">&lt;1 cm solid enhancing mass</span><span class="headingEndMark"> — </span>Surveillance is generally the most reasonable course of action for these lesions. Details are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/2970.html" rel="external">"Diagnostic approach, differential diagnosis, and management of a small renal mass", section on 'Active surveillance'</a>.)</p><p>The size cutoff of &lt;1 cm is accepted by most radiologists and urologists because such small lesions result in a low yield of diagnostic biopsies and generally have high rates of benign histology. Approximately 60 percent of &lt;1 cm kidney lesions that are selected for resection prove to be renal cell carcinoma [<a href="#rid15">15</a>]. However, malignant lesions measuring &lt;1 cm typically demonstrate indolent tumor biology, with low rates of metastatic progression and slow linear growth rates on surveillance [<a href="#rid15">15,43-46</a>]. </p><p class="headingAnchor" id="H2687617348"><span class="h2">1 to 4 cm solid enhancing mass</span><span class="headingEndMark"> — </span>Solid lesions that measure 1 to 4 cm in diameter and enhance on dedicated kidney imaging with CT or MRI are categorized as small renal masses  (<a class="graphic graphic_diagnosticimage graphicRef142924" href="/d/graphic/142924.html" rel="external">image 11</a>). </p><p>Although the majority are renal cell carcinomas, approximately 20 percent are benign tumors (eg, fat-poor angiomyolipoma, oncocytoma) [<a href="#rid6">6,15,43</a>]. Management options include resection, thermal ablation, and active surveillance with some undergoing biopsy for pathologic diagnosis before treatment. The management of these lesions is discussed separately. (See  <a class="medical medical_review" href="/d/html/2970.html" rel="external">"Diagnostic approach, differential diagnosis, and management of a small renal mass", section on 'Management approach'</a>.) </p><p class="headingAnchor" id="H340752167"><span class="h2">&gt;4 cm solid enhancing mass</span><span class="headingEndMark"> — </span>Most incidentally detected solid enhancing kidney lesions measuring &gt;4 cm in diameter are renal cell carcinoma [<a href="#rid6">6,15</a>]. The patient should be further evaluated with this presumptive diagnosis. Staging involves chest imaging, and pathologic confirmation of the diagnosis is obtained with surgical resection or, less commonly, needle biopsy. (See  <a class="medical medical_review" href="/d/html/2983.html" rel="external">"Clinical manifestations, evaluation, and staging of renal cell carcinoma", section on 'Diagnostic evaluation'</a>.)</p><p class="headingAnchor" id="H2011253817"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition and goal</strong> – An incidental kidney lesion is one detected on imaging performed for reasons other than for evaluation of urinary signs or symptoms. The goal of the diagnostic approach is to differentiate the vast majority of those that require no further evaluation from those that require referral for management  (<a class="graphic graphic_table graphicRef131673" href="/d/graphic/131673.html" rel="external">table 1</a>). (See <a class="local">'Approach to the differential diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lesions sometimes diagnosed at presentation</strong> – Some incidental lesions can be diagnosed based on imaging features at detection. These include simple cysts, angiomyolipomas, vascular abnormalities, and some malignancies. (See <a class="local">'Lesions sometimes diagnosed at presentation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dedicated kidney imaging</strong> – Many incidental lesions require further evaluation with abdominal computed tomography (CT) or magnetic resonance imaging (MRI) without and with contrast tailored for kidney lesion characterization. Availability of imaging technology and expertise and patient contraindications (eg, history of contrast allergy) drive the choice of modality. (See <a class="local">'Dedicated kidney imaging'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lesions not requiring further management</strong> – After CT or MRI dedicated for kidney lesion characterization, further management is not necessary for a lesion diagnosed as a pseudotumor or a Bosniak I or II cyst (see <a class="local">'Lesions not requiring further management after kidney imaging'</a> above). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lesions requiring further management</strong> – After CT or MRI dedicated for kidney lesion characterization, further management is necessary for a lesion diagnosed as equivocally enhancing on CT; a Bosniak IIF, III, or IV cyst; angiomyolipoma; focal infection; vascular abnormality; or a solid enhancing mass. (See <a class="local">'Lesions requiring further management after kidney imaging'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">O'Connor SD, Pickhardt PJ, Kim DH, et al. Incidental finding of renal masses at unenhanced CT: prevalence and analysis of features for guiding management. AJR Am J Roentgenol 2011; 197:139.</a></li><li><a class="nounderline abstract_t">Carrim ZI, Murchison JT. The prevalence of simple renal and hepatic cysts detected by spiral computed tomography. Clin Radiol 2003; 58:626.</a></li><li><a class="nounderline abstract_t">Herts BR, Silverman SG, Hindman NM, et al. Management of the Incidental Renal Mass on CT: A White Paper of the ACR Incidental Findings Committee. J Am Coll Radiol 2018; 15:264.</a></li><li><a class="nounderline abstract_t">Tada S, Yamagishi J, Kobayashi H, et al. The incidence of simple renal cyst by computed tomography. Clin Radiol 1983; 34:437.</a></li><li><a class="nounderline abstract_t">Bosniak MA. The current radiological approach to renal cysts. Radiology 1986; 158:1.</a></li><li><a class="nounderline abstract_t">Thompson RH, Kurta JM, Kaag M, et al. Tumor size is associated with malignant potential in renal cell carcinoma cases. J Urol 2009; 181:2033.</a></li><li><a class="nounderline abstract_t">Rendon RA, Stanietzky N, Panzarella T, et al. The natural history of small renal masses. J Urol 2000; 164:1143.</a></li><li><a class="nounderline abstract_t">Guðmundsson E, Hellborg H, Lundstam S, et al. Metastatic potential in renal cell carcinomas ≤7 cm: Swedish Kidney Cancer Quality Register data. Eur Urol 2011; 60:975.</a></li><li><a class="nounderline abstract_t">Cura M, Elmerhi F, Bugnogne A, et al. Renal aneurysms and pseudoaneurysms. Clin Imaging 2011; 35:29.</a></li><li><a class="nounderline abstract_t">Suzuki R, Gondo A, Jimi K, et al. [Two cases of incidentally detected renal arteriovenous fistula over ten years after renal biopsy]. Nihon Jinzo Gakkai Shi 2016; 58:33.</a></li><li><a class="nounderline abstract_t">Israel GM, Bosniak MA. An update of the Bosniak renal cyst classification system. Urology 2005; 66:484.</a></li><li><a class="nounderline abstract_t">Silverman SG, Mortele KJ, Tuncali K, et al. Hyperattenuating renal masses: etiologies, pathogenesis, and imaging evaluation. Radiographics 2007; 27:1131.</a></li><li><a class="nounderline abstract_t">Bosniak MA, Megibow AJ, Hulnick DH, et al. CT diagnosis of renal angiomyolipoma: the importance of detecting small amounts of fat. AJR Am J Roentgenol 1988; 151:497.</a></li><li><a class="nounderline abstract_t">Simpson E, Patel U. Diagnosis of angiomyolipoma using computed tomography-region of interest &lt; or =-10 HU or 4 adjacent pixels &lt; or =-10 HU are recommended as the diagnostic thresholds. Clin Radiol 2006; 61:410.</a></li><li><a class="nounderline abstract_t">Frank I, Blute ML, Cheville JC, et al. Solid renal tumors: an analysis of pathological features related to tumor size. J Urol 2003; 170:2217.</a></li><li><a class="nounderline abstract_t">Patel U, Ramachandran N, Halls J, et al. Synchronous renal masses in patients with a nonrenal malignancy: incidence of metastasis to the kidney versus primary renal neoplasia and differentiating features on CT. AJR Am J Roentgenol 2011; 197:W680.</a></li><li><a class="nounderline abstract_t">Campbell S, Uzzo RG, Allaf ME, et al. Renal Mass and Localized Renal Cancer: AUA Guideline. J Urol 2017; 198:520.</a></li><li class="breakAll">American Urologic Association. Renal mass and localized renal cancer: AUA guideline. https://www.auanet.org/guidelines/renal-cancer-renal-mass-and-localized-renal-cancer-guideline#x7071 (Accessed on May 15, 2019).</li><li><a class="nounderline abstract_t">Crispen PL, Viterbo R, Boorjian SA, et al. Natural history, growth kinetics, and outcomes of untreated clinically localized renal tumors under active surveillance. Cancer 2009; 115:2844.</a></li><li><a class="nounderline abstract_t">Kunkle DA, Crispen PL, Chen DY, et al. Enhancing renal masses with zero net growth during active surveillance. J Urol 2007; 177:849.</a></li><li><a class="nounderline abstract_t">Haramis G, Mues AC, Rosales JC, et al. Natural history of renal cortical neoplasms during active surveillance with follow-up longer than 5 years. Urology 2011; 77:787.</a></li><li><a class="nounderline abstract_t">Graversen JA, Mues AC, Pérez-Lanzac de Lorca A, Landman J. Active surveillance of renal cortical neoplasms: a contemporary review. Postgrad Med 2011; 123:105.</a></li><li class="breakAll">American College of Radiology.  ACR appropriateness criteria: indeterminate renal mass. https://acsearch.acr.org/docs/69367/Narrative/ (Accessed on May 15, 2019).</li><li><a class="nounderline abstract_t">Kang SK, Zhang A, Pandharipande PV, et al. DWI for Renal Mass Characterization: Systematic Review and Meta-Analysis of Diagnostic Test Performance. AJR Am J Roentgenol 2015; 205:317.</a></li><li><a class="nounderline abstract_t">Mytsyk Y, Dutka I, Yuriy B, et al. Differential diagnosis of the small renal masses: role of the apparent diffusion coefficient of the diffusion-weighted MRI. Int Urol Nephrol 2018; 50:197.</a></li><li><a class="nounderline abstract_t">Newatia A, Khatri G, Friedman B, Hines J. Subtraction imaging: applications for nonvascular abdominal MRI. AJR Am J Roentgenol 2007; 188:1018.</a></li><li><a class="nounderline abstract_t">Kambadakone A, Arasu VA, Samir AE, et al. Qualitative assessment of enhancement in a renal mass: contribution of subtraction CT. J Comput Assist Tomogr 2012; 36:381.</a></li><li><a class="nounderline abstract_t">Bellini D, Panvini N, Laghi A, et al. Systematic Review and Meta-Analysis Investigating the Diagnostic Yield of Dual-Energy CT for Renal Mass Assessment. AJR Am J Roentgenol 2019; 212:1044.</a></li><li><a class="nounderline abstract_t">Salameh JP, McInnes MDF, McGrath TA, et al. Diagnostic Accuracy of Dual-Energy CT for Evaluation of Renal Masses: Systematic Review and Meta-Analysis. AJR Am J Roentgenol 2019; 212:W100.</a></li><li><a class="nounderline abstract_t">Johnson PT, Horton KM, Fishman EK. How not to miss or mischaracterize a renal cell carcinoma: protocols, pearls, and pitfalls. AJR Am J Roentgenol 2010; 194:W307.</a></li><li><a class="nounderline abstract_t">Tsili AC, Argyropoulou MI, Gousia A, et al. Renal cell carcinoma: value of multiphase MDCT with multiplanar reformations in the detection of pseudocapsule. AJR Am J Roentgenol 2012; 199:379.</a></li><li><a class="nounderline abstract_t">Zhang J, Pedrosa I, Rofsky NM. MR techniques for renal imaging. Radiol Clin North Am 2003; 41:877.</a></li><li><a class="nounderline abstract_t">Vogel C, Ziegelmüller B, Ljungberg B, et al. Imaging in Suspected Renal-Cell Carcinoma: Systematic Review. Clin Genitourin Cancer 2019; 17:e345.</a></li><li><a class="nounderline abstract_t">Atri M, Tabatabaeifar L, Jang HJ, et al. Accuracy of Contrast-enhanced US for Differentiating Benign from Malignant Solid Small Renal Masses. Radiology 2015; 276:900.</a></li><li><a class="nounderline abstract_t">Chang EH, Chong WK, Kasoji SK, et al. Diagnostic accuracy of contrast-enhanced ultrasound for characterization of kidney lesions in patients with and without chronic kidney disease. BMC Nephrol 2017; 18:266.</a></li><li><a class="nounderline abstract_t">Eisenbrey JR, Kamaya A, Gummadi S, et al. Effects of Contrast-Enhanced Ultrasound of Indeterminate Renal Masses on Patient Clinical Management: Retrospective Analysis From 2 Institutions. J Ultrasound Med 2021; 40:131.</a></li><li><a class="nounderline abstract_t">Elbanna KY, Jang HJ, Kim TK, et al. The added value of contrast-enhanced ultrasound in evaluation of indeterminate small solid renal masses and risk stratification of cystic renal lesions. Eur Radiol 2021; 31:8468.</a></li><li><a class="nounderline abstract_t">Mousessian PN, Yamauchi FI, Mussi TC, Baroni RH. Malignancy Rate, Histologic Grade, and Progression of Bosniak Category III and IV Complex Renal Cystic Lesions. AJR Am J Roentgenol 2017; 209:1285.</a></li><li><a class="nounderline abstract_t">Smith AD, Remer EM, Cox KL, et al. Bosniak category IIF and III cystic renal lesions: outcomes and associations. Radiology 2012; 262:152.</a></li><li><a class="nounderline abstract_t">Steiner MS, Goldman SM, Fishman EK, Marshall FF. The natural history of renal angiomyolipoma. J Urol 1993; 150:1782.</a></li><li><a class="nounderline abstract_t">Nelson CP, Sanda MG. Contemporary diagnosis and management of renal angiomyolipoma. J Urol 2002; 168:1315.</a></li><li><a class="nounderline abstract_t">Sosa-Barrios RH, Burguera V, Rodriguez-Mendiola N, et al. Arteriovenous fistulae after renal biopsy: diagnosis and outcomes using Doppler ultrasound assessment. BMC Nephrol 2017; 18:365.</a></li><li><a class="nounderline abstract_t">Johnson DC, Vukina J, Smith AB, et al. Preoperatively misclassified, surgically removed benign renal masses: a systematic review of surgical series and United States population level burden estimate. J Urol 2015; 193:30.</a></li><li><a class="nounderline abstract_t">Pierorazio PM, Johnson MH, Ball MW, et al. Five-year analysis of a multi-institutional prospective clinical trial of delayed intervention and surveillance for small renal masses: the DISSRM registry. Eur Urol 2015; 68:408.</a></li><li><a class="nounderline abstract_t">Jewett MA, Mattar K, Basiuk J, et al. Active surveillance of small renal masses: progression patterns of early stage kidney cancer. Eur Urol 2011; 60:39.</a></li><li><a class="nounderline abstract_t">Schieda N, Krishna S, Pedrosa I, et al. Active Surveillance of Renal Masses: The Role of Radiology. Radiology 2022; 302:11.</a></li></ol></div><div id="topicVersionRevision">Topic 116643 Version 18.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21701022" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Incidental finding of renal masses at unenhanced CT: prevalence and analysis of features for guiding management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12887956" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The prevalence of simple renal and hepatic cysts detected by spiral computed tomography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28651987" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Management of the Incidental Renal Mass on CT: A White Paper of the ACR Incidental Findings Committee.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6872451" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : The incidence of simple renal cyst by computed tomography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3510019" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : The current radiological approach to renal cysts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19286217" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Tumor size is associated with malignant potential in renal cell carcinoma cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10992354" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : The natural history of small renal masses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21741160" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Metastatic potential in renal cell carcinomas≤7 cm: Swedish Kidney Cancer Quality Register data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21237416" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Renal aneurysms and pseudoaneurysms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26950979" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : [Two cases of incidentally detected renal arteriovenous fistula over ten years after renal biopsy].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16140062" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : An update of the Bosniak renal cyst classification system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17620471" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Hyperattenuating renal masses: etiologies, pathogenesis, and imaging evaluation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3044036" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : CT diagnosis of renal angiomyolipoma: the importance of detecting small amounts of fat.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16679114" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Diagnosis of angiomyolipoma using computed tomography-region of interest&lt;or =-10 HU or 4 adjacent pixels&lt;or =-10 HU are recommended as the diagnostic thresholds.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14634382" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Solid renal tumors: an analysis of pathological features related to tumor size.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21940540" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Synchronous renal masses in patients with a nonrenal malignancy: incidence of metastasis to the kidney versus primary renal neoplasia and differentiating features on CT.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28479239" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Renal Mass and Localized Renal Cancer: AUA Guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28479239" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Renal Mass and Localized Renal Cancer: AUA Guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19402168" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Natural history, growth kinetics, and outcomes of untreated clinically localized renal tumors under active surveillance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17296355" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Enhancing renal masses with zero net growth during active surveillance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21167561" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Natural history of renal cortical neoplasms during active surveillance with follow-up longer than 5 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21293090" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Active surveillance of renal cortical neoplasms: a contemporary review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21293090" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Active surveillance of renal cortical neoplasms: a contemporary review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26204281" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : DWI for Renal Mass Characterization: Systematic Review and Meta-Analysis of Diagnostic Test Performance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29230706" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Differential diagnosis of the small renal masses: role of the apparent diffusion coefficient of the diffusion-weighted MRI.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17377038" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Subtraction imaging: applications for nonvascular abdominal MRI.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22805664" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Qualitative assessment of enhancement in a renal mass: contribution of subtraction CT.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30835518" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Systematic Review and Meta-Analysis Investigating the Diagnostic Yield of Dual-Energy CT for Renal Mass Assessment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30714831" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Diagnostic Accuracy of Dual-Energy CT for Evaluation of Renal Masses: Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20308475" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : How not to miss or mischaracterize a renal cell carcinoma: protocols, pearls, and pitfalls.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22826400" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Renal cell carcinoma: value of multiphase MDCT with multiplanar reformations in the detection of pseudocapsule.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14521200" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : MR techniques for renal imaging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30528378" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Imaging in Suspected Renal-Cell Carcinoma: Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25919803" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Accuracy of Contrast-enhanced US for Differentiating Benign from Malignant Solid Small Renal Masses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28793871" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Diagnostic accuracy of contrast-enhanced ultrasound for characterization of kidney lesions in patients with and without chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32657452" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Effects of Contrast-Enhanced Ultrasound of Indeterminate Renal Masses on Patient Clinical Management: Retrospective Analysis From 2 Institutions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33912992" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : The added value of contrast-enhanced ultrasound in evaluation of indeterminate small solid renal masses and risk stratification of cystic renal lesions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28981360" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Malignancy Rate, Histologic Grade, and Progression of Bosniak Category III and IV Complex Renal Cystic Lesions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22106359" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Bosniak category IIF and III cystic renal lesions: outcomes and associations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8230504" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : The natural history of renal angiomyolipoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12352384" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Contemporary diagnosis and management of renal angiomyolipoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29262805" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Arteriovenous fistulae after renal biopsy: diagnosis and outcomes using Doppler ultrasound assessment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25072182" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Preoperatively misclassified, surgically removed benign renal masses: a systematic review of surgical series and United States population level burden estimate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25698065" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Five-year analysis of a multi-institutional prospective clinical trial of delayed intervention and surveillance for small renal masses: the DISSRM registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21477920" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Active surveillance of small renal masses: progression patterns of early stage kidney cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34812670" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Active Surveillance of Renal Masses: The Role of Radiology.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
